Background : Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients.
Because cancer cells multiply rapidly, they take in a high concentration of alkylating agents, and their DNA is frequently exposed and rarely repaired.
So they die off more often than most other cells, which have time to fix damaged DNA and don't accumulate the same concentrations of alkylating agents.